Myrtle L. Jones

Garnet BioTherapeutics, Inc. develops products that speed healing and reduce scarring after surgery or dermatologic procedures. It is a clinical stage regenerative medicine company that discovers, develops, and delivers new regenerative therapies by leveraging the intrinsic ability of adult somatic cells to repair, regenerate, and remodel tissue in acute and chronic disease settings. The firm's manufacturing and technology platform is a scalable GMP-compliant manufacturing process that can be applied to multiple cell types including adult bone marrow-derived stromal cells, smooth and skeletal muscle cells, dermal fibroblasts, chondrocytes, pre-adipocytes, and endothelial cells. The company was founded by Hubert J.P. Schoemaker on November 26, 2003 and is headquartered in Malvern, PA.